Document is current
Any future updates will be listed below
-
Authors
Ikeda, Kazuki https://orcid.org/0000-0003-0407-0420
Asakura, Nobuhiko
Sengoku, Soyogi
Tsukamoto, Eiki
Funahashi, Nobuaki
Koshikawa, Naohiko https://orcid.org/0000-0002-4539-888X
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (25K02482)
MEXT | Japan Society for the Promotion of Science (23K10865)
Japan Agency for Medical Research and Development (25fk0210151)
- License Information
-
More Information
Article History
Received: 4 January 2026
Revised: 26 May 2026
Accepted: 16 June 2026
First Online: 29 June 2026
Competing interests
: The authors declare no competing interests.
: All animal experiments were approved by the Institutional Animal Care and Use Committee of the Institute of Science Tokyo (Approval No. D2022020-2) and were performed in accordance with the institutional guidelines and relevant national regulations for the care and use of laboratory animals. All experiments involving recombinant DNA were approved by the Institutional Biosafety Committee of the Institute of Science Tokyo (Approval No. I2025019) and conducted in compliance with the institutional regulations and applicable guidelines governing recombinant DNA research. The analyses of human tumor protein expression RPPA data were performed using publicly available datasets obtained from The Cancer Proteome Atlas (TCPA). These datasets contain de-identified information and are exempt from additional institutional ethical review and informed consent requirements.
: All authors have read and approved the final version of the manuscript and consent to its publication in Cell Death & Disease.
